Denali Therapeutics Inc. (DNLI) Operating cash flow 2016–2025
Denali Therapeutics Inc. (DNLI) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$412.6MFY2025 · since FY2016: -$71.9M → -$412.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$412.6M | -18.7% |
| FY2024 | -$347.7M | +2.9% |
| FY2023 | -$358.0M | -46.3% |
| FY2022 | -$244.7M | -15.8% |
| FY2021 | -$211.4M | -150.8% |
| FY2020 | $416.2M | +374.6% |
| FY2019 | -$151.6M | -402.5% |
| FY2018 | $50.1M | +165.4% |
| FY2017 | -$76.6M | -6.6% |
| FY2016 | -$71.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More DNLI financial trends
DNLI RevenueDNLI Net incomeDNLI Net marginDNLI Gross profitDNLI Gross marginDNLI Operating incomeDNLI Operating marginDNLI Free cash flowDNLI Capital expendituresDNLI Return on equityDNLI Stock buybacksDNLI Dividends paidDNLI Total assetsDNLI Total liabilitiesDNLI Shareholders’ equityDNLI overview →